Clarification Of Non-Renouncable Entitlement Offer Details
Filed with ASX · · 10 pages · English
Sydney, Australia – 2 May 2022: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company) is responding to numerous queries from shareholders in relation to the upcoming Non-Renounceable Entitlement Offer (Offer) by providing a summary of the key dates for the Offer and other important information. Authorisation & Additional Information This announcement was authorised by the Board of Directors of O
Earlier from OncoSil Medical
- OncoSil Launches $10m Capital Raising
- OncoSil Signs Commercial Agreement With Hospital In Spain
- First Commerical Pancreas Treatment In Spain
- Fully-Funded Trial Approved In Germany
- Half Yearly Report Results
Later from OncoSil Medical
- OncoSil Entitlement Offer Booklet
- Entitlement Offer Results and Shortfall Notification
- OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC
- FY 2023 Strategic Update
- Bupa UK Approves Reimbursement for OncoSil in the UK
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical